| Aug 1, 2025 | Iantrek | $42.0M Series C | U.S. Venture Partners | aMoon Fund, Casey Tansey, Civilization Ventures, Radius Special Situations Fund, Visionary Ventures |
| Oct 1, 2024 | Evommune | $120.0M Series C | RA Capital Management, Sectoral Asset Management | Andera Partners, Arix Bioscience, Pivotal bioVenture Partners, RA Capital, Ysios Capital |
| Apr 2, 2024 | Miach Orthopaedics | $20.0M Series B Extension | — | Joyce Erony, Aperture Venture Partners, Endeavour Vision, Major League Soccer Players Association, Miach Orthopaedics, NFL Players Association, Smith & Nephew, SV Health Investors |
| Mar 1, 2024 | Phagenesis | $42.0M Series D | Drew Burdon, Michael Sjostrom | BOM Brabant Ventures, EQT Life Sciences, Aphelion, Ian Connatty, Duncan Johnson |
| Jan 16, 2024 | Noctrix Health | $40.0M Series C | Michael Sjostrom | Angelini Ventures, Asahi Kasei, Evan Caplan, ResMed, Tracy Pappas |
| Jul 14, 2023 | CurvaFix | $39.0M Series C | Eric Fritz | — |
| May 1, 2023 | Boundless Bio | $100.0M Series C | Fabio Pucci, RA Capital Management | ARCH Venture Partners, Nextech Invest, RA Capital, SignalFire, Versant Ventures, Alexandria Venture Investments, City Hill Ventures, Fidelity Management & Research Company, GT Healthcare Capital Partners, Logos Capital, Nextech Invest, PFM Health Sciences, Piper Heartland Healthcare Capital, Redmile Group, Surveyor Capital, Vertex Ventures HC, Wellington Management |
| Mar 7, 2023 | LENZ Therapeutics | $83.5M Series B | Stefan Mathias Larson | Clare Ozawa, Chris Dimitropoulos, Point72, RA Capital Management, RTW Investments, Versant Ventures |
| Jan 25, 2023 | Miach Orthopaedics | $40.0M Debt / Series B | Endeavour Vision, Sectoral Asset Management | Joyce Erony, NFL Players Association, Silicon Valley Bank, Smith & Nephew |
| Jan 3, 2023 | Apnimed | $79.8M Series C Extension | Chris Dimitropoulos | Tao Capital Partners |
| Jan 1, 2023 | Amolyt Pharma | $140.0M Series C | Toby Sykes, Cédric Moreau | Andera Partners, Bioqube Ventures, Domain Associates, EQT Life Sciences, Forbion, Kurma Partners, Pontifax Venture Capital, Sanofi Ventures, Ysios Capital, Vincent Brichard, ATEM Capital, Bpifrance, Credit Agricole Creation, CTI Life Sciences Fund, LSP, Mass General Brigham Ventures, Novo Holdings, OrbiMed, Relyens Innovation Sant, Tekla Capital Management |
| Aug 30, 2022 | Iantrek | $23.0M Series B | Marc-Andre Marcotte, CFA, Farrell Tyson, Jeffry Weinhuff | — |
| Jun 1, 2022 | Mineralys Therapeutics | $120.0M Series B | Andera Partners, Derek DiRocco | Access Biotechnology, Arix Bioscience, Atlas Venture, Canaan Partners, RA Capital, Versant Ventures, Ysios Capital, Boulder Ventures, Catalys Pacific, HBM Healthcare Investments, HealthCor, Rock Springs Capital, RTW Investments, Samsara BioCapital, SR One |
| May 4, 2022 | Apnimed | $62.5M Series C | Stefan Larson | Chris Dimitropoulos, Isaac Cheng, NexPoint, Seligman Private Equity Select, Tao Capital Partners |
| Apr 12, 2022 | Prilenia | $10.0M Series B Extension | — | ALS Investment Fund, Amplitude Ventures, Forbion, Morningside, Sands Capital, Houman Ashrafian, Talisman |
| Feb 22, 2022 | Magnolia Medical Technologies | $46.0M Other Equity | Ovid Amadi, Marc-Andre Marcotte, CFA | Canepa Advanced Healthcare Fund, HealthQuest Capital, Janus Henderson Investors, Sightline Partners |
| Nov 1, 2021 | Prilenia | $43.0M Series B | Morningside, Michael Ginder | Arcus Ventures, Forbion, ALS Investment Fund, Amplitude Ventures, Talisman |
| Sep 1, 2021 | Amolyt Pharma | $80.0M Series B | Raphael WISNIEWSKI, Sectoral Asset Management | Bioqube Ventures, Domain Associates, EQT Life Sciences, Kurma Partners, Pontifax Venture Capital, Vincent Brichard, ATEM Capital, Bpifrance, Credit Agricole Creation, Eurazeo, LSP, Mass General Brigham Ventures, Novo Holdings, OrbiMed, Turenne Capital |
| Jul 1, 2021 | Turnstone Biologics | $80.0M Series D | Santhosh Palani, PhD, CFA, Point72 | KohFounders, Sofinnova Investments, venBio, Venrock, Versant Ventures, 404 Bio, Brace Pharma Capital, CaaS Capital Management, Eventide Asset Management, F-Prime Capital, JM Family Enterprises, Northleaf Capital Partners, OrbiMed, Ridgeback Capital Investments, Sixty Degree Capital, Surveyor Capital, Takeda Ventures, Teralys Capital |
| Jun 17, 2021 | Cagent Vascular | $9.0M Other Equity | Sectoral Asset Management | — |
| Feb 1, 2021 | Pipeline Therapeutics | $80.0M Series C | — | Buff Gold Ventures, Versant Ventures, Casdin Capital, Franklin Templeton, Perceptive Advisors, Red Tree Venture Capital, Samsara BioCapital, Suvretta Capital Management |
| Jan 1, 2021 | Neuros Medical | $39.0M Series B | Amzak Health Investors, Marc-Andre Marcotte, CFA | Aperture Venture Partners, EQT Life Sciences, Osage University Partners, Casey Tansey, Andrew Farquharson, U.S. Venture Partners |
| Jul 21, 2020 | CurvaFix | $10.8M Series B | Marc-Andre Marcotte, CFA | — |
| Jun 1, 2020 | Checkmate Pharmaceuticals | $85.0M Series C | Oren K. Isacoff, M.D., Nilesh Kumar | Andreessen Horowitz, Cofounders Capital, F-Prime Capital Partners, Locus Ventures, Carol Gallagher, NextView Ventures, Omega Funds, Runway Growth Capital, SV Health Investors, The Column Group, The House Fund, venBio, Vida Ventures, XX, Y Combinator, James Park, Jason Wang, Jon Brelig, Manik Gupta, Ralph Gootee, BrightEdge, Decheng Capital, F-Prime Capital, Medicxi, Sofinnova Ventures |
| May 1, 2020 | Atea Pharmaceuticals | $220.0M Series D | Bain Capital Life Sciences | Adage Capital Management, Ally Bridge Group, Cormorant Asset Management, Morningside Ventures, Omega Funds, Perceptive Advisors, RA Capital Management, Redmile Group, Rock Springs Capital, T. Rowe Price Associates |
